Dupixent (dupilumab) - Indicated for moderate-to-severe atopic dermatitis not adequately controlled with topical prescription therapies or when those therapies are not advisable in children aged 6 years or older.
Jublia (efinaconazole) - Indication for onychomycosis expanded to include children as young as 6 years.
Taltz (ixekizumab) - Indication for plaque psoriasis expanded to include children aged 6 years or older.
Eucrisa (crisaborole topical) - Indicated for mild-to-moderate atopic dermatitis in infants and children aged 3 months or older.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: FDA Drug Approvals, Dermatology — 2020 Midyear Review - Medscape - Aug 14, 2020.
Comments